News AZ makes case for hypophosphatasia drug after phase 3 miss AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?
News BioMarin snaps up Alesta's lead asset for $275m BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
News AZ considers filings for long-acting Strensiq follow-up AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
Digital AI, start-ups, and the future of human health: AION Labs’ Ma... In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.